The group also suggested the role of ANXA1 as an anti‐inflammatory mediator in cardiovascular therapeutics should not be overlooked and have highlighted several studies that show the benefits of ANXA1 and its synthetic peptide in atherosclerosis [64], stroke [65] and MI [66]. This evidence concerns the gene ANXA1 and stroke disorder.